Reports Q3 revenue $157M, consensus $130.51M. “The third quarter was a watershed moment for Ionis, as we made important progress advancing our Ionis-owned medicines. With two independent launches now underway, and two more anticipated in 2026, we are delivering on our goal to bring a steady cadence of new medicines to people in need,” said Brett Monia, chief executive officer of Ionis. “Last month, we announced groundbreaking, positive topline Phase 3 results for olezarsen in severe hypertriglyceridemia and for zilganersen in Alexander disease, with regulatory filings planned in the coming months. Our approved and late-stage portfolio continues to deliver – positioning Ionis for substantial growth while, most importantly, offering the opportunity to profoundly improve the lives of people with serious diseases.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- AMZN, BABA, NTLA, XYZ: Cathie Wood Loads Up on Intellia, Block, Amazon & Alibaba, Cuts Stake in Shopify and Other Growth Stocks
- Ionis Pharmaceuticals’ Phase 3 Study on Angelman Syndrome: A Potential Game-Changer
- Ionis Pharmaceuticals Advances in MECP2 Duplication Syndrome Treatment
- Ionis Pharmaceuticals’ HALOS Study: A New Hope for Angelman Syndrome
- Ionis Pharmaceuticals’ Olezarsen Study: A Potential Game-Changer for Severe Hypertriglyceridemia